-
Product Insights
Liver Transplant Rejection - Drugs In Development, 2024
Empower your strategies with our Liver Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or regrow. Liver transplantation replaces an injured or diseased liver with a healthy one; an entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it....
-
Product Insights
Primary Sjogren's Syndrome - Drugs In Development, 2024
Empower your strategies with our Primary Sjogren's Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Primary Sjogren's Syndrome is a common chronic autoimmune disorder that affects the lacrimal and salivary glands, and some may develop extra glandular involvement of joints, GI tract, lungs, skin, CNS, and kidneys. Dry eyes and dryness of mouth are characteristic features of this condition. Joint pain, skin rashes, and dry cough are some other symptoms. Eye drops treat dry eyes which...
-
Product Insights
Pulmonary Sarcoidosis - Drugs In Development, 2024
Empower your strategies with our Pulmonary Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary Sarcoidosis is a rare inflammatory disease that affects the multi-organs predominantly lungs and intrathoracic lymph nodes. It is characterized by the presence of granulomas in which group of cells form clusters of inflamed tissue. Younger and middle-aged groups are commonly affected and there is no specific origin causing this condition. It is differentiated into five different stages from stage 0 to...
-
Product Insights
Delayed Graft Function (DGF) - Drugs In Development, 2024
Empower your strategies with our Delayed Graft Function (DGF) – Drugs In Development, 2024 report and make more profitable business decisions. Delayed graft function (DGF) is an indication of acute kidney injury (AKI) occurring after a kidney transplant, with attributes unique to the transplant process. AKI is defined as an increase in serum creatinine within 48 hours of an inciting event. In the case of a transplant, the timing is less straightforward. The diagnosis of DGF is complicated by a variety...
-
Product Insights
Corneal Graft Rejection - Drugs In Development, 2024
Empower your strategies with our Corneal Graft Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Corneal graft rejection comprises a sequence of complex immune responses that involves the recognition of the foreign histocompatibility antigens of the corneal graft by the host's immune system, leading to the initiation of the immune response cascade. An efferent immune response is mounted by the host immune system against these foreign antigens culminating in rejection and graft decompensation in irreversible cases...
-
Product Insights
Immunoglobulin G4-Related Disease (IgG4-RD) - Drugs In Development, 2024
Empower your strategies with our Immunoglobulin G4-Related Disease (IgG4-RD) – Drugs In Development, 2024 report and make more profitable business decisions. Immunoglobulin-G4 related disease is an immune-mediated condition that can affect multiple organ systems. It is a fibro-inflammatory condition with tumefactive lesions of unknown etiology and characteristic histopathological features. This is also known as IgG4-related systemic disease, hyper-IgG4 disease, IgG4-related autoimmune disease, IgG4-associated disease, IgG4-related sclerosing disease, and IgG4-syndrome. The Immunoglobulin G4-Related Disease (IgG4-RD) drugs in development market research report provide...
-
Product Insights
Juvenile Rheumatoid Arthritis - Drugs In Development, 2024
Empower your strategies with our Juvenile Rheumatoid Arthritis – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in kids and teens. It typically causes joint pain and inflammation in the hands, knees, ankles, elbows and/or wrists. But, it may affect other body parts too . JIA used to be called juvenile rheumatoid arthritis (JRA), but the name changed because it is not a kid version of the...
-
Product Insights
Pancreatic Islet Transplant Rejection - Drugs In Development, 2024
Empower your strategies with our Pancreatic Islet Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatic Islet Transplant Rejection is a process in which a transplant recipient's immune system attacks the transplanted Pancreatic Islets. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play essential roles in the immunopathogenesis of rejections The Pancreatic Islet Transplant Rejection drugs in development market research report provide comprehensive information on the therapeutics under development for Pancreatic Islet Transplant...
-
Product Insights
Subacute Cutaneous Lupus Erythematosus (SCLE) - Drugs In Development, 2024
Empower your strategies with our Subacute Cutaneous Lupus Erythematosus (SCLE) – Drugs In Development, 2024 report and make more profitable business decisions. Subacute cutaneous lupus (SCLE) is an autoimmune disorder, that occurs when the immune system attacks itself. This is a subtype of CLE presenting as symmetric, non-scarring photosensitive erythematous rash usually over syn-exposed areas like face, neck, arms, upper back, and shoulders that causes skin rashes or lesions (sores). The Subacute Cutaneous Lupus Erythematosus (SCLE) drugs in development market research...
-
Thematic Analysis
Cell and Gene Therapies in Rheumatology - Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Rheumatology Market Report Overview The market size for cell and gene therapies (CGT) in rheumatic diseases by molecule type is estimated to be $24 million in 2024. Cell therapies will continue to dominate the CGT market in rheumatic diseases. This growth is attributed to the high number of cell therapy assets in the pipeline and increasing interest in rheumatic diseases due to the increasing prevalence and high unmet need, especially as the aging population increases....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.